Irinotecan in the treatment of elderly patients with advanced colorectal cancer

Critical Reviews in Oncology/Hematology

Volumn 68, Issue 3, 2008, Pages 250-255

  Sastre, Javier ^a   Puente, Javier ^a   García Saenz, Jose A ^a   Díaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Colorectal cancer; Elderly patients; Irinotecan

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADVANCED CANCER; ASTHENIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERANCE; GERIATRIC PATIENT; HUMAN; MONOTHERAPY; NEUTROPENIA; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; MALE;

EID: 54349113525     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.05.008     Document Type: Review

References (21)

1. Saltz L.B., Cox J.V., Blande C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 (2000) 905-914
2. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
3. Cunningham D., Pyrhönen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 (1998) 1413-1418
4. Rougier Ph, Van Cutsem E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion alter fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 (1998) 1407-1412
5. Extreman M., and Aapro M. Assessment of the older cancer patients. Hematol/Oncol Clin North Am 14 (2000) 63-77
6. Rothenberg M.L., Cox J.V., DeVore R., et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85 (1999) 786-795
7. Chabot G.G., Abigerges D., Catimel G., et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6 (1995) 141-151
8. Pitot H.C., Goldberg R.M., Reid J.M., et al. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 6 (2000) 2236-2244
9. Miya T., Goya T., Fujii H., et al. Factors affecting the pharmacokinetics of CPT-11: The body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 19 (2001) 61-67
10. Schaaf L., Ichpurani N., Elfring G., et al. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G) in patients with previously treated colorectal cancer. Proc Am Soc Clin Oncol 16 (1996) 202a
11. Van Cutsem E., Dirix E., Van Laethem J.L., et al. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer 92 (2005) 1055-1062
12. Freyer G., Rougier P., Bugat R., et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. Br J Cancer 83 (2000) 431-437
13. Comella P., Farris A., Lorusso V., et al. Irinotecan plus leucovorin-modulated 5-fluorouracil i.v bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma. Br J Cancer 89 (2003) 992-996
14. Chau I., Norman A.R., Cunningham D., et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 91 (2004) 1453-1458
15. Mitry E., Douillard J.-Y., Van Cutsem E., et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 15 (2004) 1013-1017
16. Folprecht G., Seymour M.T., Saltz L., et al. Irinotecan/Fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: Combined analysis of 2.691 patients in randomized controlled trials. J Clin Oncol 26 (2008) 1443-1451
17. Barrueco J., Marshall J., Mitchell E., et al. Safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in mCRC patients >65 years compared with those <65 years: The BICC-C study. Proc Am Soc Clin Oncol 25 (2007) 182s
18. Sastre J., Marcuello E., Masutti B., et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a spanish cooperative group for the treatment of digestive tumors study. J Clin Oncol 23 (2005) 3545-3551
19. Souglakos J., Pallis A., Kakolyris S., et al. Combination of irinotecan (CPT-11) plus 5-Fluorouracil and leucovorin (FOLFIRI Regimen) as first-line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 69 (2005) 384-390
20. Mitry E., Phelip J.M., Bonnetain F., et al. Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001-02 trial): results of a planned interim analysis. Gastrointestinal Cancers Simposium (2008) [Abstract 281]
21. Rosati G., and Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori 92 (2006) 290-294